Adipokines, insulin resistance and hyperandrogenemia in obese patients with polycystic ovary syndrome: cross-sectional correlations and the effects of weight loss.
Title | Adipokines, insulin resistance and hyperandrogenemia in obese patients with polycystic ovary syndrome: cross-sectional correlations and the effects of weight loss. |
Publication Type | Journal Article |
Year of Publication | 2012 |
Authors | Spanos, N., Tziomalos K., Macut D., Koiou E., Kandaraki E. A., Delkos D., Tsourdi E., & Panidis D. |
Journal | Obes Facts |
Volume | 5 |
Issue | 4 |
Pagination | 495-504 |
Date Published | 2012 |
ISSN | 1662-4033 |
Keywords | Adipokines, Adiponectin, Adult, Anti-Obesity Agents, Body Mass Index, Case-Control Studies, Cross-Sectional Studies, Female, Humans, Hyperandrogenism, Insulin Resistance, Lactones, Leptin, Nicotinamide Phosphoribosyltransferase, Obesity, Polycystic Ovary Syndrome, Resistin, Waist Circumference, Weight Loss, Young Adult |
Abstract | OBJECTIVE: To assess the effects of weight loss on serum adipokine levels in polycystic ovary syndrome (PCOS).METHODS: We determined serum leptin, adiponectin, resistin, and visfatin levels in 60 overweight/obese women with PCOS and 48 BMI-matched female volunteers. Measurements were repeated after 24 weeks of treatment with orlistat 120 mg 3 times per day along with an energy-restricted diet.RESULTS: At baseline, serum visfatin concentration was higher in patients with PCOS than in controls (p = 0.036); serum levels of leptin, adiponectin, and resistin did not differ between the two groups. After 24 weeks, a significant reduction in BMI and waist circumference was observed in both patients with PCOS and controls (p < 0.001 vs. baseline in both groups). Also serum leptin levels decreased in both patients with PCOS and controls (p < 0.001 vs. baseline in both groups). The reduction in serum leptin levels did not differ between groups. Serum adiponectin, resistin, and visfatin levels did not change in either group.CONCLUSIONS: Leptin, adiponectin, and resistin do not appear to play major pathogenetic roles in overweight/obese patients with PCOS. In contrast, visfatin emerges as a potentially important mediator of the endocrine abnormalities of these patients. However, serum visfatin levels are not substantially affected by weight loss. |
DOI | 10.1159/000341579 |
Alternate Journal | Obes Facts |
PubMed ID | 22854419 |